Breaking: Serious collision on main Letterkenny/ Lifford road

first_img Arranmore progress and potential flagged as population grows Emergency services are currently attending the scene of a serious two vehicle collision on the main Letterkenny/Lifford road this morning.The crash between a tractor and a car happened just before 7am near Drumoghill.The road is expected to remain closed for much of today with motorists advised to allow extra time for your journey and expect delays.Traffic is currently being diverted through Stranorlar.There are no further details at this stage. Pinterest News, Sport and Obituaries on Monday May 24th Twitter Important message for people attending LUH’s INR clinic WhatsApp By News Highland – January 12, 2018 Google+ Loganair’s new Derry – Liverpool air service takes off from CODA Twitter Nine til Noon Show – Listen back to Monday’s Programme center_img Facebook Google+ Pinterest RELATED ARTICLESMORE FROM AUTHOR Previous articleIrish Water urged to outline timeline of works for LetterkennyNext articleLEADER funding deadline fast approaching News Highland WhatsApp Breaking: Serious collision on main Letterkenny/ Lifford road Facebook Homepage BannerNews Community Enhancement Programme open for applicationslast_img read more

Learn more →

Briefly Noted: Overland Park holding 9/11 remembrance ceremony this morning

first_imgMembers of the Overland Park Fire Department recognize the 15th anniversary of the Sept. 11 attacks last year.Overland Park remembering 9/11 in ceremony this morning. Members of the Overland Park Fire Department and Police Department this morning will take part in the annual ceremony remembering those lost in the 9/11 attacks. The commemoration takes place from 7:30 to 9:30 a.m. at the Overland Park Fire Training Center, 12401 Hemlock.Kansas officials report death from vaping-related lung disease. Kansas health officials have confirmed the first death in the state associated with an outbreak of serious lung disease related to vaping or using e-cigarettes. The recent death was a Kansas resident over the age of 50. According to Kansas State Epidemiologist Farah Ahmed, the patient had a history of underlying health issues and was hospitalized with symptoms that progressed rapidly. The national investigation has not identified any specific vaping or e-cigarette products linked to all cases. Many patients report using vaping or e-cigarette products with liquids that contain cannabinoid products, such as tetrahydrocannabinol. Kansas does not have detailed information on what types of products were used by the deceased. To date, Kansas has six reports associated with the outbreak. Three patients have been classified as confirmed or probable cases and three cases are still under investigation. The Centers for Disease Control and Prevention, with the addition of the Kansas report, is reporting 6 deaths and more than 450 possible cases of severe lung injury in 33 states and one jurisdiction. While investigations into these cases continue, the CDC is recommending people avoid vaping or using e-cigarettes. Also, people with a history of vaping who are experiencing lung injury symptoms should seek medical care. Nationally, symptoms among cases included shortness of breath, fever, cough, and vomiting and diarrhea. Other symptoms reported by some patients included headache, dizziness and chest pain. For individuals wanting more information on how to quit tobacco products, call 1-800-QUIT-NOW.Applications for Leadership Lenexa 2020 now available. Leadership Lenexa, Leadership Lenexa is a program of the Lenexa Chamber of Commerce to educate area business and community professionals in various aspects affecting life and business in the local community. Topics include education, local and state government, team building, economic development and organizations and issues that shape the KC metro region. Click here for session dates and more information. Here is a PDF application. For questions, contact Julie Steiner at [email protected] or 913-888-1414 ext. 206.last_img read more

Learn more →

Board to discuss en banc option

first_imgBoard to discuss en banc option Board to discuss en banc option The Florida Bar Board of Governors will consider a First District Court of Appeal en banc ruling where one judge, in a concurring opinion, strongly criticized a fellow judge.The issue was brought to the board at its July 28 meeting by a member of the Board of Governors. The case involved a criminal appeal of former Senate President and former Escambia County Commissioner W. D. Childers. The board member said the concurring opinion raised serious concerns about professionalism and the limits of judicial independence. It was noted that the concurring opinion in the Florida case did not address the legal merits of the case but instead focused on whether a fellow judge should have recused himself.Bar President Hank Coxe said the matter would be discussed at the September meeting of the Board of Governors. Coxe urged every member of the board to read the First District Court of Appeals’ June 28 opinion and February 2 opinion in Wyon Dale Childers v. State of Florida, case no. 1D03-2154, before the board’s September meeting.Coxe noted that the matter was currently pending before the Florida Supreme Court and that all members of the board needed to read the decision before it could be discussed. August 15, 2006 Regular Newslast_img read more

Learn more →

Novel neurodegenerative disease and gene identified with the help of man’s best friend

first_imgShare LinkedIn Genetic analyses revealed a single nucleotide change in the ATG4D gene in affected dogs. The ATG4D gene functions as a part of an intracellular pathway called autophagy, which functions in normal cellular “cleaning” by degrading damaged cellular components and organelles. Autophagy plays also an important role in maintaining cellular functions under stressful conditions, such as nutrient deprivation. The affected Lagottos had signs of altered autophagy in the brain.The ATG4D gene has not been previously linked to inherited diseases and represents an excellent candidate for human neurodegenerative disorders. “Our genetic finding enables more detailed future studies to unravel the disease-causing mechanisms and to understand the role of autophagy in normal neuronal function. These results could also have a broader significance for understanding and treating neurodegenerative disorders”, says Professor Hannes Lohi. Dogs could also help to explore novel therapy options for neurodegeneration.Gene test helps breeding and veterinary diagnosticsThis gene discovery enabled the development of a gene test to identify mutation carriers and to improve the Lagotto Romagnolo breeding program. “The genetic test not only helps in breeding decisions but can also be used for veterinary diagnostics. There are other similar neurodegenerative diseases in the breed and the genetic test can be used to get a differential diagnosis. This will also help ongoing studies in rest of the neurological disorders in the breed”, tells the first author of the paper, PhD student Kaisa Kyöstilä. This study is a part of her doctoral thesis work.“The signs and the rate of progression of the neurological abnormalities in this newly identified neurodegenerative disease vary considerably. The first clinical sign noticed by the dog owners can be episodes of abnormal eye movements (nystagmus) but in some cases the main clinical sign is a slowly progressive ataxia. The rate of progression of clinical signs varies from month to years. The diagnosis cannot be confirmed with clinical examinations and thus, the definitive diagnosis can only be made with the gene test” highlights Tarja Jokinen, a board-certified neurologist who participated in the studies at the University of Helsinki.The study involved a team of geneticists, veterinary neurologists and pathologists from several different European countries and highlights the importance of collaboration between basic and clinical research in veterinary medicine. Pinterest Share on Facebookcenter_img Email Share on Twitter A breakthrough study performed in an international collaboration led by Professor Tosso Leeb from the University of Bern and Professor Hannes Lohi from the University of Helsinki together with the veterinary neurologists and neuropathologists at the Faculty of Veterinary Medicine in the University of Helsinki has identified a gene mutation that causes a novel type of neurodegenerative disease in dogs. The results of the study shed light into the function of neurons, provide a new gene for human neurodegenration, and may aid in developing better treatments for neurodegenerative disorders. The study was published in the prestigious journal PLoS Genetics on 15.4.2015.Finnish and Swiss investigators have made a genetic breakthrough in the Lagotto Romagnolo dog breed. The breed originates from Italy and is known for its skills in truffle hunting. These dogs have interested genetic researchers due to the existence of several rare neurological conditions in the breed. The current study revealed a novel type of neurodegenerative disease, characterized by cerebellar dysfunction and movement incoordination. Some affected dogs also suffered from abnormal eye movements and developed behavioral changes, such as restlessness and aggression. The onset of the clinical signs varies from 4 months to 4 years.Gene discovery sheds light to a disease mechanismlast_img read more

Learn more →

Study suggests statins reduce deaths in severe flu infections

first_imgDec 15, 2011 (CIDRAP News) – The use of statins—widely used lipid-control drugs—was associated with a 41% lower death rate in patients who were hospitalized with influenza, according to a surveillance study from the 2007-08 flu season that spanned 10 states.Over the past several years, researchers have identified possible statin benefits for other diseases. For flu, the drugs have the potential to inhibit the release of cytokines, pro-inflammatory chemicals that are thought to play a role in the type of severe pathophysiologic changes in seen in human H5N1 avian flu infections.Studies to gauge the effect of statins on flu have produced mixed results. But the latest study, published yesterday in the Journal of Infectious Diseases (JID), is the first to limit the analysis to lab-confirmed flu cases.The analysis is based on data from the influenza hospitalization surveillance system of the US Center for Disease Control and Prevention’s Emerging Infections Program, which encompasses 59 counties in 10 states. Demographic and clinical data were collected from each patient’s medical record, and the researchers obtained flu vaccination information from charts, registries, physicians, or patients.The researchers recorded any statin use before or during hospitalization, but they did not collect the dose or frequency.Surveillance subjects included adults who were hospitalized between Oct 1, 2007, and Apr 30, 2008, within 14 days of a positive influenza test. Testing methods included viral culture, immunofluorescence antibody staining, reverse-transcriptase polymerase chain reaction (PCR), a commercial rapid flu test, serologic testing, or an unspecified test noted in the patient’s records.With 3,043 patients included in the analysis, the average age was 70.4 years, and 56% were women. More than half (57.1%) had been vaccinated, and 33.3% (1,013) were given statins before or during hospitalization. Of that group, 76% were on statins before and during hospitalization. Those who used statins were more likely to be male and white, to have a cardiac or other underlying medical condition, and to have been vaccinated against flu.Of the study group, 151 (5%) died within 30 days after their flu diagnosis, the majority of them shortly after hospital discharge.After controlling for age, race, underlying medical conditions, vaccination status, and antiviral use, the researchers reported a 41% reduction (adjusted odds ratio, 0.59; 95% confidence interval, 0.38-0.92) in mortality in patients who took statins before or during hospitalization.The results agree with the findings of two other studies that explored links between statins and flu mortality, but those studies used broader disease classifications that included pneumonia, rather than lab-confirmed flu, according to the authors.However, they said a 2010 study found no benefits from statin use for acute respiratory infections in a primary care setting. That study didn’t assess prescription adherence and used different disease end points that didn’t include more severe outcomes. “Statins may be more beneficial at preventing disease outcomes, such as death, but may not play a role in reducing the incidence of infection or minor illness,” the authors wrote.Several limitations citedThe researchers detailed three main limitations of their findings: testing issues, limitations of chart data, and the possibility of a “healthy user bias” in people who take statins.They noted that the study cohort may not reflect all patients hospitalized with flu, including those who weren’t tested for the disease. Also, the limited sensitivity of the rapid tests could lead to underestimation of the number of cases.According to the CDC, the sensitivity of rapid flu tests ranges from 50% to 70%, and their accuracy is influenced by the level of flu in the community. False-negatives are more likely when disease prevalence is high.Ann Thomas, MD, MPH, the study’s corresponding author and a public health physician with the Oregon Public Health Division, in an e-mail detailed the percentages for the flu confirmation methods: 75% rapid test, 11% direct immunofluorescent assay (DFA), 11% cell culture, and 6% PCR. She said the total exceeds 100% because some patients with positive rapid tests likely had other confirmatory tests.She said that, since the 2009 H1N1 pandemic, clinicians have become more interested in knowing the subtype, and PCR has now become the dominant test to identify flu cases for the Emerging Infections Program surveillance system. However, before that time, including the 2007-08 flu season, about 75% of the surveillance systems cases were diagnosed by rapid test.She noted that most of the cases during the study were identified during peak flu season, when the positive predictive value of rapid testing is higher, which Thomas said makes the study group hopeful that the test results are accurate.It’s unlikely that statin use would be associated with false-positive rapid test results or that death is more or less likely in subjects with false-positive results, she wrote. “My guess would be that inclusion of patients who did not really have influenza would bias us towards the null,” she saidExploring statin use in patients who had negative rapid tests would require the investigators to do chart abstractions, which they weren’t able to do because they didn’t collect information on that group, Thomas noted.Another challenge the researchers had was determining the true number of deaths. Since the study relied mainly on chart data, they attempted to clarify the number of deaths by reviewing local vital statistics records to see if any of the hospitalized patients died within 30 days of hospital discharge.The reliance on chart data also made it difficult for the researchers to assess the underlying functional health status of the patients, which they wrote could influence the relationship between statins and flu severity, introducing a possible “healthy user” bias. However, they noted that the statin users were older, had more underlying conditions, and had longer hospital stays, suggesting that their baseline health was no better than that of patients not taking the drugs.The researchers concluded that their findings suggest that statins are a promising area for further study and could be a useful adjunct to antiviral medication and vaccines, especially when viruses aren’t susceptible to medication or when the flu vaccine is in short supply or not well matched to the circulating strains.Future studies—ideally randomized controlled trials—exploring a possible role for statins in treating influenza should include analysis of functional status, dose and duration of therapy, statin use in younger patients, and identification of the most effective class of statins, they wrote.Slowly mounting evidenceIn an editorial in JID yesterday, Dr Edward Walsh, with the Infectious Diseases Division at the University of Rochester School of Medicine in New York, wrote that the findings are a significant addition to the slowly mounting evidence that statins may reduce annual flu burden and deaths, because the study links deaths to lab-confirmed flu.As in many observational studies, unrecognized factors, such as the “healthy user” bias, may affect the results and conclusion, Walsh wrote, noting that similar concerns have been raised about flu vaccine efficacy in older people.The analysis did not find that the influenza vaccine and antivirals reduced the number of deaths, though it did show a nonsignificant benefit for antivirals, he pointed out.Walsh said the findings raise several key questions about the relationship between statins and flu deaths, such as what mechanism is responsible. For example, he said it’s unclear if statins are more effective in flu complicated by bacterial infection or if the main benefit is due to anti-inflammatory effects that help prevent heart attacks and strokes during flu epidemics. It’s often difficult to assess the cause of deaths in chart review studies, so scientists can only speculate about what statin mechanisms might provide a benefit, he wrote.More high-quality prospective observational studies are needed to confirm the findings, but a randomized trial of the effects of long-term statin use on flu outcomes would be logistically difficult, and clinicians probably wouldn’t administer statins solely to reduce flu severity, Walsh said.However, he said such studies could support the use of statins in a pandemic setting, a strategy suggested in 2006 by David Fedson, MD, an internationally known vaccine expert. Fedson has said that if research confirms the benefits of statins for flu patients, they may offer hope for patients in countries where antiviral and vaccine supplies are scarce.Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2011 Dec 14 [Abstract]Walsh E. Statins and influenza: can we move forward? (Editorial) J Infect Dis 2011 Dec 14 [Extract]See also:Jun 30, 2006, CIDRAP News story “Paris meeting airs avian flu impacts, possible treatment”last_img read more

Learn more →

New Mexico Delegation Leads Bipartisan, Bicameral Effort In Project ECHO To Expand Telehealth Care

first_imgWASHINGTON, D.C. ― U.S. Senators Tom Udall (D-N.M.) and Martin Heinrich (D-N.M.) and U.S. Representatives Ben Ray Lujan (D-N.M.), Deb Haaland (D-N.M.), and Xochitl Torres Small (D-N.M.) led a group of 39 lawmakers Wednesday in calling on Health and Human Services (HHS) Secretary Alex Azar to support Project ECHO (Extension for Community Healthcare Outcomes), a telehealth mentoring model developed in New Mexico that enhances health care and workforce capacity in underserved areas. Project ECHO provides community-based primary care teams with the evidence-based knowledge and training needed to manage patients with complex conditions. Specifically, the New Mexico delegation encouraged HHS to use existing authorities under Medicare and Medicaid to expand Project ECHO’s reach nationwide. “The Department of Health and Human Services has identified value-based care as one of four core priorities to improve the health and well-being of the American people. In order to achieve that worthy objective, we must identify and support new and emerging health care delivery models in Medicare and Medicaid,” wrote the lawmakers. “We believe that Project ECHO, and technology-enabled collaborative learning and capacity-building models more generally, help to move us closer to this goal.” In addition to being a successful tool for tackling hard-to-treat diseases, the Project ECHO model has been used to treat behavioral health issues, improve patient care and satisfaction, increase knowledge and reduce isolation for providers, and improve retention rates for physicians in rural, underserved areas. Project ECHO is also looking for innovative ways to democratize information so medical professionals can get the support and professional development they need to keep up with the rapidly changing world of medicine. “Despite growing interest and some financial support from the federal government and specific states, no ongoing funding streams exist to support Project ECHO, and technology-enabled collaborative learning and capacity building models more broadly.  We respectfully request your consideration of the below actions—using existing authorities—that could accelerate ECHO’s integration into the health care delivery system, and, in doing so, advance federal and state efforts to provide value-based care,” the lawmakers wrote. The full letter can be found below and HERE.center_img “We’re grateful for the bipartisan support from Congress for using technology enabled collaborative learning to get better care to people in rural and underserved parts of the country who need it most,” said Dr. Sanjeev Arora, founder and director of Project ECHO. “Guidance from CMS on financing strategies through Medicaid and Medicare will make it easier for states to start up or expand existing ECHO projects. It will help keep people in their communities getting good care from providers they know and trust.” Congressional Delegation News: Project ECHO is a telehealth model that was developed in New Mexico and connects primary care physicians in rural or underserved areas with specialists to provide coordinated care and improve outcomes for patients, particularly in communities with limited access specialty care services. Originally designed to combat the Hepatitis-C epidemic in New Mexico, Project ECHO now enables patients to get treatment for a diverse array of disease conditions from various levels of health care providers, and it has grown to serve communities nationwide and internationally. The letter was also signed by U.S. Senators John Barrasso (R-Wyo.), Mazie Hirono (D-Hawaii), Brian Schatz (D-Hawaii), Kirsten Gillibrand (D-N.Y.), Jacky Rosen (D-Nev.), Maggie Hassan (D-N.H.), Jeanne Shaheen (D-N.H.), Shelley Moore Capito (R-W.V.), Tim Kaine (D-Va.), Jon Tester (D-Mont.), Angus King (I-Maine), Tina Smith (D-Minn.), Bill Cassidy (R-La.), Roger Wicker (R-Miss.), Amy Klobuchar (D-Minn.), Ben Cardin (D-Md.), Joe Manchin (D-W.V.), Kyrsten Sinema (D-Ariz.), Jeff Merkley (D-Ore.), & Patty Murray (D-Wash.) and U.S. Representatives Peter DeFazio (D-Ore.), Kurt Schrader (D-Ore.), David McKinley (R-Ore.), Bobby Rush (D-Ill.), Raja Krishnamoorthi (D-Ill.), Brad Schneider (D-Ill.), Tulsi Gabbard (D-Hawaii), Pete Stauber (D-Minn.), Josh Harder (D-Calif.), Ann Kuster (D-N.H.), Kim Schrier (D-Wash.), Danny Davis (D-Ill.), Suzan DelBene (D-Wash.), Tom Cole (R-Okla.), Ben McAdams (D-Utah), Chris Pappas (D-N.H.), Kevin Hern (R-O.K.), Cheri Bustos (D-Ill.), & Collin Peterson (D-Minn.)last_img read more

Learn more →

I-CAR Announces 2016 International Board Of Directors And Executive Committee

first_imgI-CAR, the Inter-Industry Conference on Auto Collision Repair, announced its 2016 International Board of Directors and executive committee following its strategic planning session and annual membership meeting in Orlando, Florida, held during the week of March 7. AdvertisementClick Here to Read MoreAdvertisementThe board of directors is comprised of representatives from each of the following six industry segments:collision repair; insurance; OEM vehicle manufacturers; equipment, tools and supplies; education, training and research; and related industry services.James Roach (American Honda Motor Co.) will lead as chair of the executive committee. In addition, the following will serve on the executive committee: Timothy O’Day, Gerber Collision & Glass (vice chair); Chris Evans, State Farm Insurance Co. (treasurer); Mark Woirol, Tech-Cor (secretary); Ron Vincenzi, Oakland Auto Body, A Cooks Collision Company (member-at-large); Eugene Scambray, Copart (member-at-large); and Joseph Laurentino, National General Insurance Co. (immediate past chair).The remaining directors include:­Mark Algie, 3MMark Allen, Audi of AmericaJohn Donley, IAnetJohn Eck, General Motors Co.Jim Guthrie, Car Crafters Inc.Tim Hession, GEICORobert Hills, Universal Technical Institute (UTI)Richard Perry, Chief Automotive TechnologiesRoy Schnepper, Butler’s Collision Inc.Randy Stabler, Pride Collision Centers Inc.Kyle Thompson, USAAMarcy Tieger, Symphony Advisors LLCRick Tuuri, AudaExplore ­- a Solera Company, Education Foundation RepresentativeGary Wano, GW & Son Auto Body, Inc.Michele Wyatt, Mutual of Enumclaw Insurance Co.Roach said, “Every vehicle owner expects that their collision-damaged car will be properly and safely repaired. Our industry is obliged to meet these expectations, despite the challenges posed by more sophisticated and rapidly changing vehicle technology. The I-CAR Board of Directors has never been more committed to fulfilling its vision of providing every person in the industry with the information, knowledge and skills required to perform complete, safe and quality repairs for the ultimate benefit of the consumer.”AdvertisementThe overall strategic direction for I-CAR is set by the board of directors. In addition, the board of directors also assists in obtaining resources in support of the I-CAR Mission.last_img read more

Learn more →

Carol Kruse Elected To Valvoline Board Of Directors

first_imgValvoline has announced the election of Carol Kruse, chief marketing officer of Cambia Health Solutions, to its board of directors, effective Dec. 4.AdvertisementClick Here to Read MoreAdvertisement“Carol is an extremely accomplished marketing professional, excelling in consumer brand marketing, sports and entertainment marketing, technology platform design and development, and consumer acquisition, retention and engagement through digital, mobile and social channels,” said Stephen Kirk, chairman of the board at Valvoline. “She is as equally comfortable with consumer insights and creative delivery as she is with data and technology. Carol’s deep knowledge and experience in these areas will be invaluable to Valvoline and we are excited to have her join our board.”Kruse has been senior vice president and chief marketing officer of Cambia Health Solutions since 2014. Cambia Health Solutions is a nonprofit total health solutions company consisting of 20 companies reaching more than 70 million Americans nationwide. Before assuming this role, she served as senior vice president and chief marketing officer at ESPN. Prior to that, she spent nearly 10 years at The Coca-Cola Co., moving from vice president of interactive marketing to vice president, global digital marketing.She holds a master’s degree in business administration from the University of Southern California and a bachelor’s degree in international relations from Pomona College.Kruse will serve as a member of the board’s Compensation and Governance & Nominating committees.Additional information about Valvoline’s board of directors can be found at valvoline.com.last_img read more

Learn more →

Amazon Warriors beat Zouks by 3 wickets

first_img Share 21 Views   no discussions Tweet NewsSports Amazon Warriors beat Zouks by 3 wickets by: – July 18, 2015 Sharecenter_img Sharing is caring! Share Providence, Guyana: A phenomenal bowling spell from Sunil Narine, for the Guyana Amazon Warriors, helped them to victory against the St Lucia Zouks in the Hero Caribbean Premier League. His four overs cost just six runs as he once again proved why he is the most sought after spinner in Twenty20 cricket. Having been set 112 to win, the Amazon Warriors made hard word of getting there as they reached their victory target with three wickets and 12 balls in hand, with Denesh Ramdin seeing them home with 39 not out.The Zouks batted first and the bowler that looked most likely to break their prolific opening partnership appeared to be left-arm spinner, Veersammy Permaul. He almost had Andre Fletcher dismissed stumped with the second ball of the match and had an incredibly close LBW shout against Johnson Charles turned down.Charles could not make the most of his apparent good fortune, he was bowled by David Wiese for 11 (9). Although it was the South African quick bowler that got that first breakthrough, it was Permaul that was causing the most issues for the batsman as he varied his pace beautifully to keep the opposition guessing. He completed his full allocation of four overs in that opening spell, claiming figures of 1-17 in the process.The Zouks made it to 43-1 at the end of the Powerplay, but they should have been two wickets down. Pietersen smashed the ball straight to Umar Akmal in the covers only for the Pakistani international to drop a very simple chance. Pietersen was on 16 at the time.Sunil Narine was introduced into the attack in the seventh over and he was in the wickets straight away as he completely changed the complexion of the innings. He dismissed Fletcher LBW with a top spinner that shot on to the batsman. Delorn Johnson was promoted up the order as a left-handed pinch-hitter. The experiment lasted one ball, Johnson going for a golden duck when he smashed his first ball straight up in the air.Narine continued the wicket taking in his next over when he got another LBW, this time it was the Zouks’ captain, Pietersen, that was trapped in front of his stumps for 24. The spinner was unplayable on a Providence pitch that took real turn. After two overs he had taken three wickets for just one run. He finished with 3-6 in a spell that included 18 dot balls.The spinners terrorised the Zouks throughout their innings, with even the part time tweakers of Brad Hodge claiming the wicket of Kyle Mayers. The St Lucians managed only two boundaries between the sixth and 17th over as the spinners completely tied down their opponents. A partnership of 43 between Ross Taylor and Henry Davids gave the Zouks total some respectability as they made it to 111-7, but it was never going to be enough.The first two overs were a perfect start for the Amazon Warriors as they made it to 19 without loss, but a wicket maiden in Johnson’s first over brought the Zouks back into things. The Guyanese side had made it to 47-1 off their Powerplay overs.Just as Narine had done so for the Amazon Warriors, Keron Cottoy made a massive difference as he recorded career best figures of 4-18.A change of ball, as a result of dew soaking the innings began with, led to an immediate change in momentum as Cottoy picked up the wickets of Simmons and Brad Hodge in the space of three balls. Things got even more interesting when the young leg spinner dismissed Umar Akmal LBW, but a big inside edge should have saved the batsman.Cottoy’s contribution became even more telling when he bowled Christopher Barnwell for seven with a full ball that the batsman missed while trying to play an expansive drive. In the same over Wiese was run out for a duck going for a single that wasn’t there. A further run out saw the Amazon Warriors loose six wickets for 18 runs to leave them 83-7.As the Zouks looked around for spin options, Pietersen turned to Fletcher for his first ever over in Twenty20 cricket. The Zouks just did not have enough runs to defend, but they fought brilliantly until the end. A Permaul six sealed the win in a thrilling match that was enjoyed by a big crowd in Providence as he and his skipper saw their team home.This win takes the Amazon Warriors to second place in the table, and, with two home games remaining, they are well placed to make the latter stages of the event, conceivably as table toppers going straight to the final.For the Zouks they finish their 10 matches with nine points. At present they sit in fourth place and would make the knockout games if the league were to finish today, but with all of the other teams having games in hand their final finishing position will depend on how results go over the next few days.last_img read more

Learn more →

Chelsea player keen to stay at club, knocked back China approach,…

first_imgThe website claims that the defender is really keen on staying at the London side, and will do what is needed to renew his contract with the club.With his current deal expiring in 2019, Luiz doesn’t mind Chelsea’s procedure of extending deals of elder players for only one year.UOL says that Luiz’s representatives have recently been in China, where they received an approach for the player. The 31-year-old, however, has claimed that he’d rather stay at the Stamford Bridge at this point.Embed from Getty ImagesThe report claims that the player is pretty well adapted to London, where he lives close to Willian and has a restaurant to take care of.Speaking to the Brazilian media, Luiz has many times explained how happy he is at Chelsea with the arrival of Maurizio Sarri, especially after the problematic season he had under Antonio Conte.by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksTrending TodayForge of Empires – Free Online GameBuild a City, Trade With Your Neighbors, Play With Your FriendsForge of Empires – Free Online GameUndoRaid: Shadow Legends | Free DownloadEven Non-Gamers Are Obsessed With This RPG Game (It’s Worth Installing!)Raid: Shadow Legends | Free DownloadUndoKeto减肥1個簡單的妙招一夜「融化」腹部贅肉(今晚試試)Keto减肥UndoPerfect-Dating.comReveal Tung Chung As The Best City to Date for Love & RomancePerfect-Dating.comUndoDating.comWhere do attractive singles find each other in Tung Chung?Dating.comUndoStanChart by CNBC CatalystWill Blockchain Reduce the Global Trade Finance Gap to Reach the UN’s Sustainable Development Goals?StanChart by CNBC CatalystUndoCoworking Space | Search AdsThe cost of shared office in Hong Kong might surprise youCoworking Space | Search AdsUndoTheTopFiveVPNEnjoy Netflix Now Without Any RestrictionsTheTopFiveVPNUndo熱門話題小心會長過頭…網友推爆:「真的長得超誇張!」熱門話題Undo David Luiz’s wish to stay at Chelsea is reinforced by Brazilian outlet UOL on Friday.last_img read more

Learn more →